In addition to supportive transfusions, do you consider other interventions for symptomatic anemia and thrombocytopenia associated with chronic neutrophilic leukemia?

Assuming the CSF3R mutation that is seen is the T618I mutation, you can consider ruxolitinib. Dao et al., PMID 31880950, reported on a prospective trial of ruxolitinib in 44 patients with CNL or atypical CML. The overall response rate was 35%. However, responses were enriched in patients with CSF3R-...